EUVIMEDEUVIMED entdecken
Kohortenstudie

SGLT2 Inhibitors and Risk of Postmenopausal Bleeding in Women: An Active‐Comparator, New‐User Cohort Study

Jung Yoon Choi, Sung Yun Suh, Hee Min Lee, Susan J Lewis, Sandy Jeong Rhie iD

Diabetes, Obesity and Metabolism · 29.10.2026

DOI: 10.1111/dom.71458 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 29.10.2026. Verfasst von Jung Yoon Choi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Ministry of Education, South Korea, Ministry of Science and ICT, South Korea, Ministry of Food and Drug Safety, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

A recent case report and pharmacovigilance reports have suggested a possible association between sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and postmenopausal bleeding (PMB), but population‐level evidence is lacking. We evaluated the risk of PMB among women aged 55–90 years initiating SGLT2 inhibitors versus dipeptidyl peptidase‐4 (DPP‐4) inhibitors. Materials and Methods We conducted an active‐comparator, new‐user cohort study using data from the All of Us Research Program. Women aged 55–90 years who newly initiated either an SGLT2 inhibitor or a DPP‐4 inhibitor were included. The primary outcome was the first recorded PMB during follow‐up. Propensity score (PS) matching, with exact matching on calendar period, was used to control for confounding. Hazard ratios (HRs) and incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were estimated using Cox and Poisson regression models.

Results

Among 2603 women, 1328 initiated SGLT2 inhibitors and 1275 initiated DPP‐4 inhibitors. After 1:1 PS matching, 650 pairs achieved good covariate balance. In the matched cohort, 37 and 34 PMB events occurred over 2248.2 and 2374.2 person‐years, respectively. SGLT2 inhibitor initiation was not associated with increased PMB risk (HR 1.14, 95% CI 0.70–1.84; IRR 1.15, 95% CI 0.71–1.87). Sensitivity analyses were consistent with the primary findings.

Conclusions

SGLT2 inhibitor initiation was not associated with a significantly increased PMB risk compared with DPP‐4 inhibitor initiation. These findings did not provide evidence of increased PMB risk with SGLT2 inhibitor therapy, although wide confidence intervals and limited outcome events warrant confirmation in larger studies.

Schlagwörter

Stichwörter der Autor:innen

DPP‐IV inhibitorSGLT2 inhibitorType 2 diabetesantidiabetic drugpharmaco‐epidemiologyreal‐world evidence

Autor:innen und Institutionen

  • Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
  • Graduate School of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
  • Department of Pharmacy, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea.
  • Department of Pharmacy Practice, University of Findlay College of Pharmacy, Findlay, Ohio, USA.
  • Department of Pharmacy, Mercy Health St Anne Hospital, Toledo, Ohio, USA.

ORCID-Profile: Sandy Jeong Rhie

Förderung

  • Ministry of Education, South Korea
  • Ministry of Science and ICT, South Korea
  • Ministry of Food and Drug Safety, South Korea
  • Ministry of Food and Drug Safety

Zitieren

APA

Choi, J. Y., Suh, S. Y., Lee, H. M., Lewis, S. J., & Rhie, S. J. (2026). SGLT2 Inhibitors and Risk of Postmenopausal Bleeding in Women: An Active‐Comparator, New‐User Cohort Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71458

Vancouver

Choi JY, Suh SY, Lee HM, Lewis SJ, Rhie SJ. SGLT2 Inhibitors and Risk of Postmenopausal Bleeding in Women: An Active‐Comparator, New‐User Cohort Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71458

BibTeX
@article{Choi2026,
  author = {Choi, Jung Yoon and Suh, Sung Yun and Lee, Hee Min and Lewis, Susan J and Rhie, Sandy Jeong},
  title = {SGLT2 Inhibitors and Risk of Postmenopausal Bleeding in Women: An Active‐Comparator, New‐User Cohort Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71458}
}
Kostenlos starten →